186 related articles for article (PubMed ID: 19047983)
61. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
Fiorucci S
Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261
[TBL] [Abstract][Full Text] [Related]
62. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
63. Treatment of Barrett's esophagus with high-grade dysplasia.
McAllaster JD; Buckles D; Al-Kasspooles M
Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
[TBL] [Abstract][Full Text] [Related]
64. Chemoprevention goes gourmet: different flavors of NO-aspirin.
Goel A; Gasche C; Boland CR
Mol Interv; 2005 Aug; 5(4):207-10. PubMed ID: 16123534
[No Abstract] [Full Text] [Related]
65. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
66. The surgeon's role in cancer prevention. The model in colorectal carcinoma.
Chu DZ; Gibson G; David D; Yen Y
Ann Surg Oncol; 2007 Nov; 14(11):3054-69. PubMed ID: 17710500
[TBL] [Abstract][Full Text] [Related]
67. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
68. Commentary: aspirin and colorectal cancer an epidemiological success story.
Flossmann E; Rothwell PM
Int J Epidemiol; 2007 Oct; 36(5):962-5. PubMed ID: 17954716
[No Abstract] [Full Text] [Related]
69. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects.
Lipkin M
Cancer Res; 1988 Jan; 48(2):235-45. PubMed ID: 3275494
[No Abstract] [Full Text] [Related]
70. Endoscopic resection for Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma.
Watson TJ
Semin Thorac Cardiovasc Surg; 2008; 20(4):310-9. PubMed ID: 19251170
[TBL] [Abstract][Full Text] [Related]
71. Current and emerging treatments for mild/moderate acute ambulatory pain.
Weaver AL
Am J Ther; 2008; 15 Suppl 10():S12-6. PubMed ID: 19127123
[TBL] [Abstract][Full Text] [Related]
72. NSAIDS and esophageal cancer.
Scherübl H; Sutter AP; Zeitz M
Gastroenterology; 2003 Dec; 125(6):1914-5; author reply 1915. PubMed ID: 14727630
[No Abstract] [Full Text] [Related]
73. 5-ASA and colorectal cell-cycle progression.
Koelink PJ; Verspaget HW
Gastroenterology; 2007 Apr; 132(4):1635-6; author reply 1636. PubMed ID: 17418160
[No Abstract] [Full Text] [Related]
74. The role of dietary factors and chemoprevention in gastrointestinal malignancy.
Levin B
Curr Opin Oncol; 1995 Jul; 7(4):377-80. PubMed ID: 7578388
[TBL] [Abstract][Full Text] [Related]
75. Role of Aspirin in Gastric Cancer Prevention.
Umar A; Loomans-Kropp HA
Cancer Prev Res (Phila); 2022 Apr; 15(4):213-215. PubMed ID: 35373259
[TBL] [Abstract][Full Text] [Related]
76. Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia.
Ullah MF; Bhat SH; Husain E; Abu-Duhier F; Hadi SM; Sarkar FH; Ahmad A
Crit Rev Food Sci Nutr; 2016 Jul; 56(9):1501-18. PubMed ID: 25365584
[TBL] [Abstract][Full Text] [Related]
77. [Cancer chemoprevention-basic and clinical aspects].
Takayama T; Okamura S; Okahisa T; Kaji M; Takeuchi H; Kimura T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1067-71. PubMed ID: 18633242
[TBL] [Abstract][Full Text] [Related]
78. Gastrointestinal cancer prevention in the United States: the road ahead.
Metz DC; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):81-3. PubMed ID: 12582015
[No Abstract] [Full Text] [Related]
79. Gastrointestinal cancer: pathogenesis, risk factors and the development of intermediate biomarkers for chemoprevention studies.
Lipkin M
J Cell Biochem Suppl; 1992; 16G():1-13. PubMed ID: 1469890
[TBL] [Abstract][Full Text] [Related]
80. Clinical experiences with G17DT in gastrointestinal malignancies.
He AR; Marshall JL
Expert Rev Anticancer Ther; 2006 Apr; 6(4):487-92. PubMed ID: 16613537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
